JointHealth
français
 
JointHealth™ express   July 12, 2022


Arthritis Consumer Experts (ACE) maps out recent changes to provincial drug formulary listing decisions. It contains information about important changes to provincial drug formularies and what it means for Canadians living with inflammatory arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), and vasculitis.

The following medications have have been added to the online version of ACE’s Arthritis Medications Report Card:
  • adalimumab (Abrilada®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Simlandi®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Yuflyma®) for the treatment of RA, AS, JIA, and PsA
British Columbia

The following medication has been declined for listing in the provincial drug formulary:
  • ixekizumab (Taltz®) for the treatment of ankylosing spondylitis
Alberta

The Alberta government-sponsored drug programs previously covered the following drug product(s). Effective May 1, 2022, the listed product(s) below will no longer be a benefit. A transition period will be applied and as of June 1, 2022, claims will no longer pay.
  • adalimumab (Humira®) (20 MG/0.2 ML) 20 MG Injection Syringe
  • adalimumab (Humira®) (40 MG/0.8 ML) 40 MG Injection Syringe
A listing criteria update has occurred for the following medications:
  • adalimumab (Amgevita®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hadlima®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hulio®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hyrimoz®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Idacio®) for the treatment of RA, AS, JIA, and PsA
The following medications have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Abrilada®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Simlandi®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Yuflyma®) for the treatment of RA, AS, JIA, and PsA
Saskatchewan

A listing criteria update has occurred for the following medications:
  • tocilizumab (Actemra®) for the treatment of JIA
  • rituximab (Riximyo®) for the treatment of RA and vasculitis
  • rituximab (Ruxience®) for the treatment of RA and vasculitis
  • rituximab (Truxima®) for the treatment of RA and vasculitis
The following medications have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Abrilada®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Simlandi®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Yuflyma®) for the treatment of RA, AS, JIA, and PsA
  • rituximab (Riabni®) for the treatment of RA and vasculitis
The following medication has been declined for listing in the provincial drug formulary:
  • infliximab (Remsima®) for the treatment of RA
Manitoba

A listing criteria update has occurred for the following medications:
  • adalimumab (Hulio®) for the treatment of RA, AS, JIA, and PsA
  • tocilizumab (Actemra®) for the treatment of JIA
The following medications have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Abrilada®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Simlandi®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Yuflyma®) for the treatment of RA, AS, JIA, and PsA
  • rituximab (Riabni®) for the treatment of RA and vasculitis
  • rituximab (Riximyo®) for the treatment of vasculitis
Ontario

A listing criteria update has occurred for the following medication:
  • adalimumab (Hulio®) for the treatment of RA, AS, JIA, and PsA
The following medications have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Abrilada®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Simlandi®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Yuflyma®) for the treatment of RA, AS, JIA, and PsA
  • rituximab (Riabni®) for the treatment of RA and vasculitis
Quebec

A listing criteria update has occurred for the following medications:
  • adalimumab (Idacio®) for the treatment of RA, AS, JIA, and PsA
  • tocilizumab (Actemra®) for the treatment of JIA
The following medications have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Abrilada®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Simlandi®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Yuflyma®) for the treatment of RA, AS, JIA, and PsA
  • rituximab (Riabni®) for the treatment of RA
  • rituximab (Riximyo®) for the treatment of vasculitis
  • rituximab (Ruxience®) for the treatment of vasculitis
Nova Scotia

A listing criteria update has occurred for the following medications:
  • adalimumab (Amgevita®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hadlima®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hulio®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hyrimoz®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Idacio®) for the treatment of RA, AS, JIA, and PsA
  • rituximab (Riximyo®) for the treatment of RA
  • rituximab (Ruxience®) for the treatment of RA and vasculitis
  • rituximab (Truxima®) for the treatment of RA and vasculitis
The following medications have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Abrilada®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Simlandi®) for the treatment of RA, AS, JIA, and PsA
  • infliximab (Avsola®) for the treatment of RA, AS, and PsA
  • rituximab (Riabni®) for the treatment of RA and vasculitis
  • rituximab (Riximyo®) for the treatment of vasculitis
New Brunswick

The following medications have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Abrilada®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Simlandi®) for the treatment of RA, AS, JIA, and PsA
  • rituximab (Riabni®) for the treatment of RA and vasculitis
Newfoundland & Labrador

The following medications have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Abrilada®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Simlandi®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Yuflyma®) for the treatment of RA, AS, JIA, and PsA
A listing criteria update has occurred for the following medications:
  • adalimumab (Humira®, Amgevita®, Hadlima®, Hulio®, Hyrimoz®, Idacio®), certolizumab pegol (Cimzia®), etanercept (Enbrel®, Brenzys®, Erelzi®), golimumab (Simponi®), infliximab (Remicade®, Avsola®, Inflectra®, Renflexis®), secukinumab (Cosentyx®) for ankylosing spondylitis
Prince Edward Island

The following medications have been listed for reimbursement on the provincial drug formulary:
  • baricitinib (Olumiant®) for the treatment of RA
  • rituximab (Riabni®) for the treatment of RA and vasculitis
  • tocilizumab (Actemra®) for the treatment of vasculitis
NIHB

The following medications have been listed for reimbursement:
  • adalimumab (Abrilada®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Simlandi®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Yuflyma®) for the treatment of RA, AS, JIA, and PsA
  • baricitinib (Olumiant®) for the treatment of RA
  • etanercept (Brenzys®) for the treatment of JIA, and PsA
  • rituximab (Riabni®) for the treatment of RA and vasculitis
  • rituximab (Riximyo®) for the treatment of vasculitis
Yukon

A listing criteria update has occurred for the following medication:
  • tofacitinib citrate (Xeljanz®) for the treatment of RA
The following medications have been listed for reimbursement on the Yukon drug formulary:
  • adalimumab (Idacio®) for the treatment of RA, AS, and PsA
  • infliximab (Renflexis®) for the treatment of RA, AS, and PsA